The antibody-based drug candidate discovery process is an extensive research and development undertaking requiring broad expertise, technology and tools to deliver an end result in the form of a potential therapeutic antibody molecule.
Relying on its experience in contractual R&D on antibodies, the PureSelect2 technology platform for in vitro monoclonal antibody selection, numerous proprietary projects on therapeutic antibodies, plus combining the potential and tools provided within its other services, Pure Biologics is positioned to offer complete support in the antibody drug discovery process – from steps of target identification to lead optimization.
This total R&D service includes among others:
- antigen production,
- cell line development,
- phage display library generation;
- antibody selection,
- antibody reformatting and modification,
- biophysical and cell-based assays,
giving rise to antibody drug lead candidates with pre-defined functions and characteristics.
Pure Biologics – providing you complete biotechnological solutions.